Literature DB >> 35705601

Machine learning for comprehensive prediction of high risk for Alzheimer's disease based on chromatic pupilloperimetry.

Yael Lustig-Barzelay1,2, Ifat Sher1,2,3, Inbal Sharvit-Ginon4,5, Yael Feldman1,2, Michael Mrejen6, Shada Dallasheh1,2, Abigail Livny2,3,7,8, Michal Schnaider Beeri4,9, Aron Weller5,10, Ramit Ravona-Springer2,4,11, Ygal Rotenstreich12,13,14.   

Abstract

Currently there are no reliable biomarkers for early detection of Alzheimer's disease (AD) at the preclinical stage. This study assessed the pupil light reflex (PLR) for focal red and blue light stimuli in central and peripheral retina in 125 cognitively normal middle age subjects (45-71 years old) at high risk for AD due to a family history of the disease (FH+), and 61 age-similar subjects with no family history of AD (FH-) using Chromatic Pupilloperimetry coupled with Machine Learning (ML). All subjects had normal ophthalmic assessment, and normal retinal and optic nerve thickness by optical coherence tomography. No significant differences were observed between groups in cognitive function and volumetric brain MRI. Chromatic pupilloperimetry-based ML models were highly discriminative in differentiating subjects with and without AD family history, using transient PLR for focal red (primarily cone-mediated), and dim blue (primarily rod-mediated) light stimuli. Features associated with transient pupil response latency (PRL) achieved Area Under the Curve Receiver Operating Characteristic (AUC-ROC) of 0.90 ± 0.051 (left-eye) and 0.87 ± 0.048 (right-eye). Parameters associated with the contraction arm of the rod and cone-mediated PLR were more discriminative compared to parameters associated with the relaxation arm and melanopsin-mediated PLR. Significantly shorter PRL for dim blue light was measured in the FH+ group in two test targets in the temporal visual field in right eye that had highest relative weight in the ML algorithm (mean ± standard error, SE 0.449 s ± 0.007 s vs. 0.478 s ± 0.010 s, p = 0.038). Taken together our study suggests that subtle focal changes in pupil contraction latency may be detected in subjects at high risk to develop AD, decades before the onset of AD clinical symptoms. The dendrites of melanopsin containing retinal ganglion cells may be affected very early at the preclinical stages of AD.
© 2022. The Author(s).

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35705601      PMCID: PMC9200977          DOI: 10.1038/s41598-022-13999-0

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.996


  62 in total

1.  Melanopsin-expressing ganglion cells in primate retina signal colour and irradiance and project to the LGN.

Authors:  Dennis M Dacey; Hsi-Wen Liao; Beth B Peterson; Farrel R Robinson; Vivianne C Smith; Joel Pokorny; King-Wai Yau; Paul D Gamlin
Journal:  Nature       Date:  2005-02-17       Impact factor: 49.962

Review 2.  Developing retinal biomarkers for the earliest stages of Alzheimer's disease: What we know, what we don't, and how to move forward.

Authors:  Jessica Alber; Danielle Goldfarb; Louisa I Thompson; Edmund Arthur; Kimberly Hernandez; Derrick Cheng; Delia Cabrera DeBuc; Francesca Cordeiro; Leonardo Provetti-Cunha; Jurre den Haan; Gregory P Van Stavern; Stephen P Salloway; Stuart Sinoff; Peter J Snyder
Journal:  Alzheimers Dement       Date:  2020-01       Impact factor: 21.566

3.  Diagnostic validity of the dementia questionnaire for Alzheimer disease.

Authors:  R J Ellis; K Jan; C Kawas; W C Koller; K E Lyons; D V Jeste; L A Hansen; L J Thal
Journal:  Arch Neurol       Date:  1998-03

4.  Pupillometer-based objective chromatic perimetry in normal eyes and patients with retinal photoreceptor dystrophies.

Authors:  Alon Skaat; Ifat Sher; Andrew Kolker; Sivan Elyasiv; Elkana Rosenfeld; Mohamad Mhajna; Shlomo Melamed; Michael Belkin; Ygal Rotenstreich
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-04-17       Impact factor: 4.799

5.  The Israel Registry for Alzheimer's Prevention (IRAP) Study: Design and Baseline Characteristics.

Authors:  Ramit Ravona-Springer; Inbal Sharvit-Ginon; Ithamar Ganmore; Lior Greenbaum; Barbara B Bendlin; Shelley A Sternberg; Abigail Livny; Liran Domachevsky; Israel Sandler; Simona Ben Haim; Sapir Golan; Liat Ben-Ami; Orit Lesman-Segev; Sigalit Manzali; Anthony Heymann; Michal Schnaider Beeri
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

6.  Tropicamide effects on pupil size and pupillary light reflexes in Alzheimer's and Parkinson's disease.

Authors:  Eric Granholm; Shaunna Morris; Douglas Galasko; Clifford Shults; Erin Rogers; Boris Vukov
Journal:  Int J Psychophysiol       Date:  2003-02       Impact factor: 2.997

7.  Chromatic pupilloperimetry for objective diagnosis of Best vitelliform macular dystrophy.

Authors:  Daniel Ben Ner; Ifat Sher; Amit Hamburg; Mohamad O Mhajna; Ron Chibel; Estela Derazne; Inbal Sharvit-Ginon; Eran Pras; Hadas Newman; Jaime Levy; Samer Khateb; Dror Sharon; Ygal Rotenstreich
Journal:  Clin Ophthalmol       Date:  2019-03-05

Review 8.  Alzheimer's disease: Targeting the Cholinergic System.

Authors:  Talita H Ferreira-Vieira; Isabella M Guimaraes; Flavia R Silva; Fabiola M Ribeiro
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

9.  Pupillometry evaluation of melanopsin retinal ganglion cell function and sleep-wake activity in pre-symptomatic Alzheimer's disease.

Authors:  Angela J Oh; Giulia Amore; William Sultan; Samuel Asanad; Jason C Park; Martina Romagnoli; Chiara La Morgia; Rustum Karanjia; Michael G Harrington; Alfredo A Sadun
Journal:  PLoS One       Date:  2019-12-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.